(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, have entered into a license agreement to develop bispecific antibodies for up to three undisclosed target pairs. Almirall … Read the full press release →
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, antibodies, Dr. Chengbin Wu, EpimAb, Fabs-In-Tandem Immunoglobulin (FIT-Ig®), Karl Ziegelbauer, Multiple Targets, partnership, sustainability